Personalized cancer therapy is a treatment strategy centered on the ability to predict which patients are more likely to respond to specific cancer therapies. This approach is founded upon the idea that tumor biomarkers are associated with patient prognosis and tumor response to therapy. In addition, patient genetic factors can be associated with drug metabolism, drug response and drug toxicity. Personalized tumor molecular profiles, tumor disease site and other patient characteristics are then potentially used for determining optimum individualized therapy options.

Tumor biomarkers can be DNA, RNA, protein and metabolomic profiles that predict therapy response. However, the most recent approach is the sequencing of tumor DNA, which can reveal genomic alterations that have implications for cancer treatment. This Personalized Cancer Therapy website was specifically developed as a tool for physicians and patients to assess potential therapy options based on specific tumor biomarkers.

The global personalized cancer therapy market was valued at about USD 10.0 billion in 2015, and is expected to reach USD 19.3 billion by 2020, growing at a CAGR of 14.1% from 2016 to 2020. By the geography, North America occupies a larger market share, Asia-Pacific is the fastest growing market and is also the largest demand market, such as China and India.

The key players of the personalized cancer therapy market are Abbott Molecular (U.S.), Affymetrix (U.S.), Almac Group (UK), Asuragen (U.S.), Roche (Switzerland), Qiagen (Germany), Agilent Technologies (U.S.) etc..

Read Full Report: http://www.gosreports.com/global-personalized-cancer-therapy-industry-2016-market-research-report/

Joanna | Executive – International Business and partner Relations
E-mail: [email protected] | Tel: 510-400-8520
Web: www.gosreports.com